Treatment of canine parvoviral enteritis with interferon-omega in a placebo-controlled field trial

@article{deMari2003TreatmentOC,
  title={Treatment of canine parvoviral enteritis with interferon-omega in a placebo-controlled field trial},
  author={K de Mari and Laurence Maynard and H M Eun and Bernard Lebreux},
  journal={Veterinary Record},
  year={2003},
  volume={152},
  pages={105 - 108}
}
The clinical efficacy of a recombinant feline interferon (IFN) (type omega) was evaluated under field conditions for the treatment of dogs with parvoviral enteritis. In this multicentric, double-blind, placebo-controlled trial, 94 dogs from one to 28 months old were randomly assigned to two groups which were treated intravenously either with IFN (2·5 million units/kg) or placebo once a day for three consecutive days, and monitored for clinical signs and mortality for 10 days. Each dog received… Expand
Treatment of canine parvoviral enteritis with interferon-omega in a placebo-controlled challenge trial.
TLDR
It is confirmed that the rFeIFN-omega can exert a significant therapeutic effect on dogs with parvoviral enteritis by improving clinical signs and reducing mortality. Expand
Use of oseltamivir in the treatment of canine parvoviral enteritis.
TLDR
A clear advantage to the use of oseltamivir with standard therapy for canine parvoviral enteritis was not established, but a significant weight loss during hospitalization, as well as a significant decrease in WBC count were documented in the control group. Expand
Clinical evaluation of a single dose of immune plasma for treatment of canine parvovirus infection.
TLDR
Administration of a single 12-mL dose of immune plasma soon after the onset of CPV enteritis in dogs was not effective in ameliorating clinical signs, reducing viremia, or hastening hematologic recovery. Expand
Therapeutic Effects of Recombinant Feline Interferon-co on Feline Leukemia Virus (FeLV)-Infected and FeLV/Feline Immunodeficiency Virus (FIV)-Coinfected Symptomatic Cats
TLDR
It is demonstrated that rFeIFN-omega initially has statistically significant therapeutic effects on clinical signs and later on survival of cats with clinical signs associated with FeLV infection and FeLV/FIV coinfection. Expand
Efficacy of feline anti‐parvovirus antibodies in the treatment of canine parvovirus infection
TLDR
In vitro, canine parvovirus was fully neutralised by feline panleukopenia virus antibodies and no significant beneficial effect of passively transferred feline anti-parvov virus antibodies in the used dosage regimen was demonstrated. Expand
Clinical evaluation of hyperimmune plasma for treatment of dogs with naturally occurring parvoviral enteritis.
TLDR
HIP at 10 mL/kg IV administered to dogs with CPV within the first 6 hours of hospitalization improves markers of shock during the initial 24 hoursof hospitalization; however, this study was underpowered to evaluate these effects. Expand
Evaluation of inflammation and immunity in cats with spontaneous parvovirus infection: Consequences of recombinant feline interferon-ω administration
TLDR
Results suggest that rFeIFN should be administered to the queen, to increase passive maternal immunity, or to kittens before introduction in a potentially contaminated environment, suggesting that r FeIFN stimulates antibody production. Expand
Interferon therapies in small animals.
TLDR
Based on limited evidence, recombinant canine IFN-α could be a topical treatment option for dogs with gingivitis and keratoconjunctivitis sicca and large randomised controlled trials are needed before IFNs can be recommended for other indications. Expand
Canine parvoviral enteritis: an update on the clinical diagnosis, treatment, and prevention
TLDR
The current state of knowledge is reviewed regarding the diagnostic aspects of parvoviral enteritis, with special emphasis placed on the clinical relevance of the detection of viral antigens in the feces, detection ofiral antibodies in the serum, or the polymerase chain reaction-based amplification of the viral DNA in the poop. Expand
Increased survival in puppies affected by Canine Parvovirus type II using an immunomodulator as a therapeutic aid
TLDR
The administration of a human immunomodulator to puppies with CPE under six months of age reduces the severity of clinical signs, increases survival, and modulates inflammatory cell parameters, which might be mediated by the human Ub∆GG to canine CXCR4 interaction. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 14 REFERENCES
Treatment of canine parvoviral enteritis with interferon-omega in a placebo-controlled challenge trial.
TLDR
It is confirmed that the rFeIFN-omega can exert a significant therapeutic effect on dogs with parvoviral enteritis by improving clinical signs and reducing mortality. Expand
Inhibitory effects of recombinant feline interferon on the replication of feline enteropathogenic viruses in vitro
TLDR
Sensitivity to antiviral activities of the rFeIFN varied with cell types; Felis catus whole fetus (fcwf-4) cells were more sensitive than Crandell feline kidney cells, but no sensitivity was found for Madin-Darby canine kidney cells when vesicular stomatitis virus was used as a challenge virus. Expand
Feline interferon-omega treatment on canine parvovirus infection.
TLDR
Recombinant feline interferon-omega preparation showed good clinical efficacy on canine parvovirus infection both in an experimental trial with beagles, and in field trials. Expand
Canine parvovirus.
  • A. G. Bell
  • Medicine
  • New Zealand veterinary journal
  • 1983
TLDR
Generally puppies and adolescent dogs are at highest risk of disease, and most adult dogs have some immunity secondary to vaccination and exposure to the virus at low levels in the environment. Expand
Emergence, Natural History, and Variation of Canine, Mink, and Feline Parvoviruses
  • C. Parrish
  • Biology, Medicine
  • Advances in Virus Research
  • 1990
Publisher Summary This chapter discusses the emergence of canine parvovirus (CPV), the evidence concerning the previous emergence of mink enteritis virus (MEV) as the cause of a new disease inExpand
Homogeneous production of feline interferon in silkworm by replacing single amino acid code in signal peptide region in recombinant baculovirus and characterization of the product.
In a previous paper we reported that we constructed a recombinant baculovirus named BmFeIFN1 which produced recombinant feline interferon (FeIFN) in silkworm after infection. High purification ofExpand
Emergence and recent evolution of canine parvovirus.
  • U. Truyen
  • Biology, Medicine
  • Veterinary microbiology
  • 1999
This review summarizes the current knowledge about the emergence of canine parvovirus from an ancestor virus similar to feline panleukopenia virus most likely from a wild carnivore host. The recentExpand
Feline interferon
  • 1999
Clinical effects of the recombinant feline interferon-omega on experimental parvovirus infection in beagle dogs.
TLDR
Treatment with rFeIFN-omega can reduce severe enteritis caused by CPV-2 infection in dogs, and vomiting and anorexia were improved by treatment, suggesting a rapid effect. Expand
111/3767/92 -Good Clinical Practice for the Conduct of Clinical Trials on Veterinary Medicinial Products in the European Union
  • 1994
...
1
2
...